木犀草素在牙周炎防治中的研究进展

doi:10.13591/j.cnki.kqyx.2024.02.009

摘要/Abstract

摘要：

木犀草素是一种植物来源的天然四羟基黄酮类化合物,近年来已被广泛应用于各种炎症相关疾病的研究中,在牙周炎的防治中具有广阔的应用前景,但目前还缺乏木犀草素治疗牙周炎的相关临床试验,其发展潜能、相关作用机制及安全性仍有待进一步探索。本文就木犀草素对牙周炎相关软组织破坏以及牙槽骨吸收的影响进行综述。

关键词: 木犀草素, 牙周炎, 炎症反应, 牙槽骨吸收, 基质金属蛋白酶

Abstract:

Luteolin is a natural flavonoid with four hydroxyl groups that originates from plants. It has been extensively investigated in various inflammatory disease models in recent years, and exhibits great application prospect in the prevention and treatment for periodontitis. However, the clinical application of luteolin in periodontitis remains unexplored, and the development potential, underlying mechanisms and safety of luteolin require further investigation. This review will provide a comprehensive overview of the effects of luteolin on soft tissue destruction and alveolar bone loss associated with periodontitis.

Key words: luteolin, periodontitis, inflammatory response, alveolar bone resorption, matrix metalloproteinase

中图分类号:

R781.4

赵溟昱, 时彬冕, 谢旭东, 许春梅, 王骏. 木犀草素在牙周炎防治中的研究进展[J]. 口腔医学, 2024, 44(2): 126-129.

ZHAO Mingyu, SHI Binmian, XIE Xudong, XU Chunmei, WANG Jun. Research progress of luteolin in the prevention and treatment for periodontitis[J]. Stomatology, 2024, 44(2): 126-129.

参考文献 40

[1]	Kinane DF, Stathopoulou PG, Papapanou PN. Periodontal diseases[J]. Nat Rev Dis Primers, 2017, 3: 17038. doi: 10.1038/nrdp.2017.38 pmid: 28805207
[2]	Kwon T, Lamster IB, Levin L. Current concepts in the management of periodontitis[J]. Int Dent J, 2021, 71(6):462-476. doi: 10.1111/idj.12630 pmid: 34839889
[3]	Golub LM, Lee HM. Periodontal therapeutics: Current host-modulation agents and future directions[J]. Periodontol 2000, 2020, 82(1):186-204. doi: 10.1111/prd.v82.1
[4]	Preshaw PM. Host modulation therapy with anti-inflammatory agents[J]. Periodontol 2000, 2018, 76(1):131-149. doi: 10.1111/prd.12148 pmid: 29193331
[5]	Thomford NE, Senthebane DA, Rowe A, et al. Natural products for drug discovery in the 21st century: Innovations for novel drug discovery[J]. Int J Mol Sci, 2018, 19(6):1578. doi: 10.3390/ijms19061578
[6]	Jang SW, Cho CH, Jung YS, et al. Enzymatic synthesis of α-flavone glucoside via regioselective transglucosylation by amylosucrase from Deinococcus geothermalis[J]. PLoS One, 2018, 13(11):e0207466. doi: 10.1371/journal.pone.0207466
[7]	Casili G, Ardizzone A, Lanza M, et al. Treatment with luteolin improves lipopolysaccharide-induced periodontal diseases in rats[J]. Biomedicines, 2020, 8(10):442. doi: 10.3390/biomedicines8100442
[8]	Theoharides TC. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin[J]. Bio Factors, 2020, 46(3):306-308.
[9]	Zheng YZ, Chen DF, Deng G, et al. The surrounding environments on the structure and antioxidative activity of luteolin[J]. J Mol Model, 2018, 24(7):149. doi: 10.1007/s00894-018-3680-1
[10]	González-Alamilla EN, Gonzalez-Cortazar M, Valladares-Carranza B, et al. Chemical constituents of Salix babylonica L. and their antibacterial activity against gram-positive and gram-negative animal bacteria[J]. Molecules, 2019, 24(16):2992. doi: 10.3390/molecules24162992
[11]	Aziz N, Kim MY, Cho JY. Anti-inflammatory effects of luteolin: A review of in vitro, in vivo, and in silico studies[J]. J Ethnopharmacol, 2018, 225: 342-358. doi: S0378-8741(17)33457-8 pmid: 29801717
[12]	Li L, Luo W, Qian YY, et al. Luteolin protects against diabetic cardiomyopathy by inhibiting NF-κB-mediated inflammation and activating the Nrf2-mediated antioxidant responses[J]. Phytomedicine, 2019, 59: 152774. doi: 10.1016/j.phymed.2018.11.034
[13]	Ali F, Siddique YH. Bioavailability and pharmaco-therapeutic potential of luteolin in overcoming alzheimer’s disease[J]. CNS Neurol Disord Drug Targets, 2019, 18(5):352-365. doi: 10.2174/1871527318666190319141835
[14]	Lin Y, Liu PG, Liang WQ, et al. Luteolin-4'-O-glucoside and its aglycone, two major flavones of Gnaphalium affine D. Don, resist hyperuricemia and acute gouty arthritis activity in animal models[J]. Phytomedicine, 2018, 41: 54-61. doi: S0944-7113(18)30029-1 pmid: 29519319
[15]	Ahmed S, Khan H, Fratantonio D, et al. Apoptosis induced by luteolin in breast cancer: Mechanistic and therapeutic perspectives[J]. Phytomedicine, 2019, 59: 152883. doi: 10.1016/j.phymed.2019.152883
[16]	Ambasta RK, Gupta R, Kumar D, et al. Can luteolin be a therapeutic molecule for both colon cancer and diabetes?[J]. Brief Funct Genomics, 2018, 18(4):230-239. doi: 10.1093/bfgp/ely036 pmid: 30462152
[17]	Imran M, Rauf A, Abu-Izneid T, et al. Luteolin, a flavonoid, as an anticancer agent: A review[J]. Biomed Pharmacother, 2019, 112: 108612. doi: 10.1016/j.biopha.2019.108612
[18]	Ramadan DE, Hariyani N, Indrawati R, et al. Cytokines and chemokines in periodontitis[J]. Eur J Dent, 2020, 14(3):483-495. doi: 10.1055/s-0040-1712718 pmid: 32575137
[19]	Könönen E, Gursoy M, Gursoy UK. Periodontitis: A multifaceted disease of tooth-supporting tissues[J]. J Clin Med, 2019, 8(8):1135. doi: 10.3390/jcm8081135
[20]	Boelen GJ, Boute L, d'Hoop J, et al. Matrix metalloproteinases and inhibitors in dentistry[J]. Clin Oral Investig, 2019, 23(7):2823-2835. doi: 10.1007/s00784-019-02915-y
[21]	Balci Yuce H, Toker H, Yildirim A, et al. The effect of luteolin in prevention of periodontal disease in Wistar rats[J]. J Periodontol, 2019, 90(12):1481-1489. doi: 10.1002/JPER.18-0584 pmid: 31115905
[22]	Kurgan S, Kantarci A. Molecular basis for immunohistochemical and inflammatory changes during progression of gingivitis to periodontitis[J]. Periodontol 2000, 2018, 76(1):51-67. doi: 10.1111/prd.2018.76.issue-1
[23]	Gutiérrez-Venegas G, Jiménez-Estrada M, Maldonado S. The effect of flavonoids on transduction mechanisms in lipopolysaccharide-treated human gingival fibroblasts[J]. Int Immunopharmacol, 2007, 7(9):1199-1210. doi: 10.1016/j.intimp.2007.05.004 pmid: 17630199
[24]	Gutiérrez-Venegas G, Contreras-Sánchez A. Luteolin and fisetin inhibit the effects of lipopolysaccharide obtained from Porphyromonas gingivalis in human gingival fibroblasts[J]. Mol Biol Rep, 2013, 40(1):477-485. doi: 10.1007/s11033-012-2083-0 pmid: 23054013
[25]	Gutiérrez-Venegas G, Luna OA, Arreguín-Cano JA, et al. Myricetin blocks lipoteichoic acid-induced COX-2 expression in human gingival fibroblasts[J]. Cell Mol Biol Lett, 2014, 19(1):126-139. doi: 10.2478/s11658-014-0186-4 pmid: 24569980
[26]	Mathew G, Unnikrishnan MK. Multi-target drugs to address multiple checkpoints in complex inflammatory pathologies: Evolutionary cues for novel first-in-class anti-inflammatory drug candidates: A reviewer’s perspective[J]. Inflamm Res, 2015, 64(10):747-752. doi: 10.1007/s00011-015-0851-8
[27]	Onishi S, Tebayashi S, Hikichi Y, et al. Inhibitory effects of luteolin and its derivatives on osteoclast differentiation and differences in luteolin production by Capsicum annuum varieties[J]. Biosci Biotechnol Biochem, 2021, 85(11):2224-2231. doi: 10.1093/bbb/zbab149
[28]	López Roldán A, García Giménez JL, Alpiste Illueca F. Impact of periodontal treatment on the RANKL/OPG ratio in crevicular fluid[J]. PLoS One, 2020, 15(1):e0227757. doi: 10.1371/journal.pone.0227757
[29]	Kim TH, Jung JW, Ha BG, et al. The effects of luteolin on osteoclast differentiation, function in vitro and ovariectomy-induced bone loss[J]. J Nutr Biochem, 2011, 22(1):8-15. doi: 10.1016/j.jnutbio.2009.11.002
[30]	Song FM, Wei CM, Zhou L, et al. Luteoloside prevents lipopolysaccharide-induced osteolysis and suppresses RANKL-induced osteoclastogenesis through attenuating RANKL signaling cascades[J]. J Cell Physiol, 2018, 233(2):1723-1735. doi: 10.1002/jcp.26084 pmid: 28681916
[31]	Sharma JN, Al-Omran A, Parvathy SS. Role of nitric oxide in inflammatory diseases[J]. Inflammopharmacol, 2007, 15(6):252-259. doi: 10.1007/s10787-007-0013-x
[32]	Zhang J, Ding C, Meng XF, et al. Nitric oxide modulates the responses of osteoclast formation to static magnetic fields[J]. Electromagn Biol Med, 2018, 37(1):23-34. doi: 10.1080/15368378.2017.1414057 pmid: 29235883
[33]	Gutiérrez-Venegas G, Kawasaki-Cárdenas P, Rita Arroyo-Cruz S, et al. Luteolin inhibits lipopolysaccharide actions on human gingival fibroblasts[J]. Eur J Pharmacol, 2006, 541(1/2):95-105. doi: 10.1016/j.ejphar.2006.03.069
[34]	Agidigbi TS, Kim C. Reactive oxygen species in osteoclast differentiation and possible pharmaceutical targets of ROS-mediated osteoclast diseases[J]. Int J Mol Sci, 2019, 20(14):3576. doi: 10.3390/ijms20143576
[35]	Tomokiyo A, Wada N, Maeda H. Periodontal ligament stem cells: Regenerative potency in periodontium[J]. Stem Cells Dev, 2019, 28(15):974-985. doi: 10.1089/scd.2019.0031 pmid: 31215350
[36]	张亚龙, 孙佳瑶, 宗斌, 等. 经典Wnt信号通路与牙周膜干细胞成骨分化[J]. 口腔医学, 2021, 41(10):936-941.
[37]	Quan H, Dai XP, Liu MY, et al. Luteolin supports osteogenic differentiation of human periodontal ligament cells[J]. BMC Oral Health, 2019, 19(1):229. doi: 10.1186/s12903-019-0926-y pmid: 31655580
[38]	Jing Z, Wang CY, Yang QN, et al. Luteolin attenuates glucocorticoid-induced osteoporosis by regulating ERK/Lrp-5/GSK-3β signaling pathway in vivo and in vitro[J]. J Cell Physiol, 2019, 234(4):4472-4490. doi: 10.1002/jcp.v234.4
[39]	Hienz SA, Paliwal S, Ivanovski S. Mechanisms of bone resorption in periodontitis[J]. J Immunol Res, 2015: 615486.
[40]	Koromili M, Kapourani A, Barmpalexis P. Preparation and evaluation of amorphous solid dispersions for enhancing luteolin’s solubility in simulated saliva[J]. Polymers, 2022, 15(1):169. doi: 10.3390/polym15010169